EPS: As of FY2025 Q2, the actual value is USD 0.51.EBIT: As of FY2025 Q2, the actual value is USD -27.12 M.<h3>Segment Revenue</h3><ul><li>The company operates as a single segment focused on research, discovery, and clinical development of human gene therapy products.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $25.8 million for the three months ended April 30, 2025, compared to $15.0 million for the same period in 2024. For the six months ended April 30, 2025, the net loss was $50.4 million, compared to $25.7 million in 2024.</li><li>Research and Development Expenses: Increased by $10.4 million from $9.9 million for the three months ended April 30, 2024, to $20.2 million for the same period in 2025. For the six months ended April 30, 2025, R&amp;D expenses increased by $24.7 million from $15.5 million in 2024 to $40.2 million.</li><li>General and Administrative Expenses: Decreased by $0.5 million from $7.5 million for the three months ended April 30, 2024, to $6.9 million for the same period in 2025. For the six months ended April 30, 2025, G&amp;A expenses increased by $1.0 million from $12.6 million in 2024 to $13.6 million.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $48.6 million for the six months ended April 30, 2025, compared to $21.5 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $67.0 million for the six months ended April 30, 2025, compared to $0.7 million in 2024.</li><li>Net Cash Provided by Financing Activities: $0.2 million for the six months ended April 30, 2025, compared to $205.5 million in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance the ongoing LEGEND study of detalimogene, including the pivotal cohort of patients with BCG-unresponsive NMIBC, to completion and file a Biologics License Application with the FDA in mid-2026.</li><li>Non-Core Business: The company is exploring the clinical application of detalimogene to other forms of NMIBC and expanding the cancer indications that can be treated with detalimogene.</li><li>Priority: The company expects to incur significant expenses as it establishes medical affairs, sales, marketing, and distribution infrastructure to support the potential commercial launch of detalimogene.</li></ul>

ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 10-Q: FY2025 Q2 EPS: USD 0.51